These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

219 related items for PubMed ID: 26297058

  • 1. A clinical pharmacokinetic microdosing study of docetaxel with Japanese patients with cancer.
    Fujita K, Yoshino E, Kawara K, Maeda K, Kusuhara H, Sugiyama Y, Yokoyama T, Kaneta T, Ishida H, Sasaki Y.
    Cancer Chemother Pharmacol; 2015 Oct; 76(4):793-801. PubMed ID: 26297058
    [Abstract] [Full Text] [Related]

  • 2. Toward prediction of efficacy of chemotherapy: a proof of concept study in lung cancer patients using [¹¹C]docetaxel and positron emission tomography.
    van der Veldt AA, Lubberink M, Mathijssen RH, Loos WJ, Herder GJ, Greuter HN, Comans EF, Rutten HB, Eriksson J, Windhorst AD, Hendrikse NH, Postmus PE, Smit EF, Lammertsma AA.
    Clin Cancer Res; 2013 Aug 01; 19(15):4163-73. PubMed ID: 23620410
    [Abstract] [Full Text] [Related]

  • 3. Open-label, randomized, single-dose, crossover study to evaluate the pharmacokinetics and safety differences between two docetaxel products, CKD-810 and Taxotere injection, in patients with advanced solid cancer.
    Cho EK, Park JY, Lee KH, Song HS, Min YJ, Kim YH, Kang JH.
    Cancer Chemother Pharmacol; 2014 Jan 01; 73(1):9-16. PubMed ID: 24337589
    [Abstract] [Full Text] [Related]

  • 4. Lack of effect of aprepitant on the pharmacokinetics of docetaxel in cancer patients.
    Nygren P, Hande K, Petty KJ, Fedgchin M, van Dyck K, Majumdar A, Panebianco D, de Smet M, Ahmed T, Murphy MG, Gottesdiener KM, Cocquyt V, van Belle S.
    Cancer Chemother Pharmacol; 2005 Jun 01; 55(6):609-16. PubMed ID: 15723220
    [Abstract] [Full Text] [Related]

  • 5. Phase I dose-finding and pharmacokinetic study of docetaxel and gefitinib in patients with advanced or metastatic non-small-cell lung cancer: evaluation of drug-drug interaction.
    Motonaga M, Yamamoto N, Makino Y, Ando-Makihara R, Ohe Y, Takano M, Hayashi Y.
    Cancer Chemother Pharmacol; 2015 Oct 01; 76(4):713-21. PubMed ID: 26233803
    [Abstract] [Full Text] [Related]

  • 6. Use of microdosing to predict pharmacokinetics at the therapeutic dose: experience with 5 drugs.
    Lappin G, Kuhnz W, Jochemsen R, Kneer J, Chaudhary A, Oosterhuis B, Drijfhout WJ, Rowland M, Garner RC.
    Clin Pharmacol Ther; 2006 Sep 01; 80(3):203-15. PubMed ID: 16952487
    [Abstract] [Full Text] [Related]

  • 7. Population pharmacokinetics of HM781-36 (poziotinib), pan-human EGF receptor (HER) inhibitor, and its two metabolites in patients with advanced solid malignancies.
    Noh YH, Lim HS, Jung JA, Song TH, Bae KS.
    Cancer Chemother Pharmacol; 2015 Jan 01; 75(1):97-109. PubMed ID: 25377158
    [Abstract] [Full Text] [Related]

  • 8. A phase I trial of oxaliplatin in combination with docetaxel in patients with advanced solid tumors.
    Iqbal S, Lenz HJ, Gandara DR, Shibata SI, Groshen S, Synold TW, Newman EM.
    Cancer Chemother Pharmacol; 2013 Jul 01; 72(1):85-91. PubMed ID: 23712328
    [Abstract] [Full Text] [Related]

  • 9. Analysis of docetaxel pharmacokinetics in humans with the inclusion of later sampling time-points afforded by the use of a sensitive tandem LCMS assay.
    Gustafson DL, Long ME, Zirrolli JA, Duncan MW, Holden SN, Pierson AS, Eckhardt SG.
    Cancer Chemother Pharmacol; 2003 Aug 01; 52(2):159-66. PubMed ID: 12759775
    [Abstract] [Full Text] [Related]

  • 10. Influence of garlic (Allium sativum) on the pharmacokinetics of docetaxel.
    Cox MC, Low J, Lee J, Walshe J, Denduluri N, Berman A, Permenter MG, Petros WP, Price DK, Figg WD, Sparreboom A, Swain SM.
    Clin Cancer Res; 2006 Aug 01; 12(15):4636-40. PubMed ID: 16899612
    [Abstract] [Full Text] [Related]

  • 11. The effect of Echinacea purpurea on the pharmacokinetics of docetaxel.
    Goey AK, Meijerman I, Rosing H, Burgers JA, Mergui-Roelvink M, Keessen M, Marchetti S, Beijnen JH, Schellens JH.
    Br J Clin Pharmacol; 2013 Sep 01; 76(3):467-74. PubMed ID: 23701184
    [Abstract] [Full Text] [Related]

  • 12. Relationship of systemic exposure to unbound docetaxel and neutropenia.
    Baker SD, Li J, ten Tije AJ, Figg WD, Graveland W, Verweij J, Sparreboom A.
    Clin Pharmacol Ther; 2005 Jan 01; 77(1):43-53. PubMed ID: 15637530
    [Abstract] [Full Text] [Related]

  • 13. Comparative pharmacokinetics of weekly and every-three-weeks docetaxel.
    Baker SD, Zhao M, Lee CK, Verweij J, Zabelina Y, Brahmer JR, Wolff AC, Sparreboom A, Carducci MA.
    Clin Cancer Res; 2004 Mar 15; 10(6):1976-83. PubMed ID: 15041715
    [Abstract] [Full Text] [Related]

  • 14. Microdose study of a P-glycoprotein substrate, fexofenadine, using a non-radioisotope-labelled drug and LC/MS/MS.
    Yamazaki A, Kumagai Y, Yamane N, Tozuka Z, Sugiyama Y, Fujita T, Yokota S, Maeda M.
    J Clin Pharm Ther; 2010 Apr 15; 35(2):169-75. PubMed ID: 20456735
    [Abstract] [Full Text] [Related]

  • 15. A Phase I pharmacokinetic and biological correlative study of oblimersen sodium (genasense, g3139), an antisense oligonucleotide to the bcl-2 mRNA, and of docetaxel in patients with hormone-refractory prostate cancer.
    Tolcher AW, Kuhn J, Schwartz G, Patnaik A, Hammond LA, Thompson I, Fingert H, Bushnell D, Malik S, Kreisberg J, Izbicka E, Smetzer L, Rowinsky EK.
    Clin Cancer Res; 2004 Aug 01; 10(15):5048-57. PubMed ID: 15297406
    [Abstract] [Full Text] [Related]

  • 16. Clinical pharmacokinetics of unbound docetaxel: role of polysorbate 80 and serum proteins.
    Loos WJ, Baker SD, Verweij J, Boonstra JG, Sparreboom A.
    Clin Pharmacol Ther; 2003 Oct 01; 74(4):364-71. PubMed ID: 14534523
    [Abstract] [Full Text] [Related]

  • 17. Effects of experimental hyperlipidaemia on the pharmacokinetics of docetaxel in rats.
    Lee JH, Oh JH, Lee YJ.
    Xenobiotica; 2011 Sep 01; 41(9):797-804. PubMed ID: 21561320
    [Abstract] [Full Text] [Related]

  • 18. A pharmacokinetic interaction study of docetaxel and cisplatin plus or minus 5-fluorouracil in the treatment of patients with recurrent or metastatic solid tumors.
    Felici A, Loos WJ, Verweij J, Cirillo I, de Bruijn P, Nooter K, Mathijssen RH, de Jonge MJ.
    Cancer Chemother Pharmacol; 2006 Nov 01; 58(5):673-80. PubMed ID: 16544143
    [Abstract] [Full Text] [Related]

  • 19. Pilot Study to Predict Pharmacokinetics of a Therapeutic Gemcitabine Dose From a Microdose.
    Van Nuland M, Rosing H, Thijssen B, Burgers JA, Huitema ADR, Marchetti S, Schellens JHM, Beijnen JH.
    Clin Pharmacol Drug Dev; 2020 Nov 01; 9(8):929-937. PubMed ID: 31970932
    [Abstract] [Full Text] [Related]

  • 20. A phase I study of docetaxel with ketoconazole modulation in patients with advanced cancers.
    Yong WP, Wang LZ, Tham LS, Wong CI, Lee SC, Soo R, Sukri N, Lee HS, Goh BC.
    Cancer Chemother Pharmacol; 2008 Jul 01; 62(2):243-51. PubMed ID: 17909805
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 11.